Genitourinary Cancers | Specialty

Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer

April 18th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.

Dr. Tagawa Discusses the Development of Immunotherapy in Urothelial Cancer

April 14th 2017

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.

Dr. Quinn on the Future of Treatments for RCC

April 13th 2017

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on the future of treatments for patients with renal cell carcinoma (RCC).

Dr. Choueiri on Savolitinib in Papillary Renal Cell Cancer

April 13th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses savolitinib in papillary renal cell cancer.

Dr. Gomella on Ongoing Trials of Immunotherapy in Bladder Cancer

April 12th 2017

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.

Dr. Quinn on Combinations of Targeted Therapy in RCC

April 11th 2017

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on combinations of targeted therapies for patients with renal cell carcinoma (RCC).

Dr. Gomella Discusses Immunotherapy in Bladder Cancer

April 11th 2017

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

RCC Advances Shake Up Drug Choices

April 7th 2017

Axitinib was a promising newcomer in the renal cell carcinoma field when it was introduced as a second-line therapy 5 years ago. Now it is being displaced by newer therapies, a development that may serve as a harbinger for the evolution of treatment patterns in other tumor types with a bounty of novel agents.

Evolving Therapeutic Strategies in Renal Cell Carcinoma

April 6th 2017

David M. Nanus, MD, discusses evolving therapeutic strategies in the neoadjuvant and adjuvant setting for patients with renal cell carcinoma.

Dr. Linehan on Treatment for Hereditary Leiomyomatosis and RCC

April 4th 2017

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses the treatment of hereditary leiomyomatosis and renal cell cancer (HLRCC).

Expert Discusses Targeted Combinations in RCC

March 31st 2017

David I. Quinn, PhD, MBBS, discusses the latest advances with targeted agents in renal cell caricinoma, including combination regimens with checkpoint inhibitors.

Frontline Immunotherapy on the Horizon in Bladder Cancer

March 29th 2017

Evan Y. Yu, MD, discusses the current treatment options for patients with metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

Sacituzumab Govitecan Shows Promise in Urothelial Cancer

March 23rd 2017

Scott Tagawa, MD, discusses the latest findings with sacituzumab govitecan in patients with metastatic urothelial cancer.

Evidence Builds for Targeting PD-1/PD-L1 Pathway in Bladder Cancer

March 21st 2017

As the number of tumor types with approved PD-1/PD-L1 pathway inhibitors continues to expand, bladder cancer has become a robust area of development.

Thoughts on Metastatic Kidney Cancer

March 20th 2017

Patient Communication About Adjuvant Therapy for RCC

March 20th 2017

VEGF TKI Therapy in the Adjuvant Setting of RCC

March 20th 2017

Upfront Immunotherapy for Metastatic Kidney Cancer

March 20th 2017

CABOSUN Trial of Upfront Cabozantinib in Metastatic RCC

March 20th 2017

Treatment Beyond Progression for Metastatic RCC

March 20th 2017